Evidence map›Paper›PMID 37047172›Full record

ReviewInternational journal of molecular sciences2023

Solid Lipid Nanoparticles: Applications and Prospects in Cancer Treatment.

Durgaramani Sivadasan, Kalaivanan Ramakrishnan, Janani Mahendran, Hariprasad Ranganathan, Arjunan Karuppaiah, Habibur Rahman

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
15.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Membrane-Coated Iron Oxide (FeInternational journal of nanomedicine · 2026
    Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Durgaramani SivadasanDepartment of Pharmaceutics, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia.
Kalaivanan RamakrishnanDepartment of Pharmaceutics, PSG College of Pharmacy, Coimbatore 641004, TN, India.
Janani MahendranDepartment of Pharmaceutics, College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences, Coimbatore 641002, TN, India.
Hariprasad RanganathanDepartment of Pharmaceutical Analysis, PSG College of Pharmacy, Coimbatore 641004, TN, India.
Arjunan KaruppaiahDepartment of Pharmaceutics, Karpagam College of Pharmacy, Coimbatore 641032, TN, India.ORCID 0000-0002-8572-3990
Habibur RahmanDepartment of Pharmaceutics, PSG College of Pharmacy, Coimbatore 641004, TN, India.
Jazan University · SAKarpagam Academy of Higher Education · INSri Ramakrishna Institute of Paramedical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent advancements in drug delivery technologies paved a way for improving cancer therapeutics. Nanotechnology emerged as a potential tool in the field of drug delivery, overcoming the challenges of conventional drug delivery systems. In the field of nanotechnology, solid lipid nanoparticles (SLNs) play a vital role with a wide range of diverse applications, namely drug delivery, clinical medicine, and cancer therapeutics. SLNs establish a significant role owing to their ability to encapsulate hydrophilic and hydrophobic compounds, biocompatibility, ease of surface modification, scale-up feasibility, and possibilities of both active and passive targeting to various organs. In cancer therapy, SLNs have emerged as imminent nanocarriers for overcoming physiological barriers and multidrug resistance pathways. However, there is a need for special attention to be paid to further improving the conceptual understanding of the biological responses of SLNs in cancer therapeutics. Hence, further research exploration needs to be focused on the determination of the structure and strength of SLNs at the cellular level, both in vitro and in vivo, to develop potential therapeutics with reduced side effects. The present review addresses the various modalities of SLN development, SLN mechanisms in cancer therapeutics, and the scale-up potential and regulatory considerations of SLN technology. The review extensively focuses on the applications of SLNs in cancer treatment.

Indexed as

NanoparticlesNeoplasmsDrug CarriersDrug Delivery SystemsLipidsLiposomesDrug CarriersLipid NanoparticlesLipidsLiposomescancer therapeuticsdrug delivery mechanismlipid nanoparticle

Identifiers

PMID37047172
PMCPMC10094605
OpenAlexW4361008354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.